Kornimate/medical-research-clean huggingface dataset:
clostridium difficile virulence mechanism study (cdvm study)

Conditions: Clostridium Difficile Infection; Clostridium Difficile

Summary: this study is an observational study to collect stool samples from patients with clostridium difficile infection (cdi) to investigate the virulence mechanisms of c. difficile ribotypes in hong kong, mainly ribotype 002. no intervention is involved.

this is an observational study to collect stool samples from patients with clostridium difficile infection (cdi), aims to (1) to investigate the virulence mechanisms of c. difficile ribotype 002, by analysing its growth, cytotoxicity, and metabolite production in vitro and in vivo. the investigators also aim (2) to compare these virulence mechanisms with other common ribotypes in asia, and (3) to correlate these with important clinical outcomes. the results of this study will have a major significance to the medical and scientific community. the results of this study will have a major significance to the medical and scientific community. the mechanistic data will point to important molecular pathways that can be targeted for novel therapies; whereas the phenotypic data will inform the investigators of its virulence and therefore will be useful for disease surveillance and public health interventions. the identified toxin(s) and metabolite(s) may be useful as prognostic biomarkers to stratify patients with different outcomes, as patients with a worse outcome may require more aggressive therapy. given the prevalence and severity of this ribotype, the results will be useful for gastroenterologists, microbiologists, infectious diseases physicians and public health specialists in the asia pacific region.

Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis of cdi, as documented by diarrheal symptoms and positive stool test result for c. difficile toxin or toxigenic c. difficile, or colonoscopic findings of pseudomembranous colitis (pmc). * patients aged over or equal to 18 years old. * patients able and willing to provide informed consent. exclusion criteria: * patients with concomitant infection by other microbes such as salmonella, campylobacter, vibrio, shigella, and escherichia coli. * patients under 18 years old. * patients who cannot give consent.

Keywords: ribotypes hong kong virulence mechanism
stress hyperglycemia. potential role of incretin analogs

Conditions: Hyperglycemia; Critical Illness

Summary: this is a prospective observational study to examine the levels of glucoregulatory hormones, with special focus on incretins levels, in critically ill patients with stress hyperglycemia.


Eligibility criteria:
inclusion criteria: * age \> 18 years * emergent icu admission * written informed consent from patient or relative. exclusion criteria: * previously known type i or type ii diabetes. * patients who received insulin or oral antidiabetic agents before icu admission. * malignancies. * scheduled surgery * patients receiving enteral or parenteral nutrition. * inability to obtain informed consent.

Keywords: stress hyperglycemia incretins glp-1 gip glucoregulatory hormones
ethnic differences in the impact of breast cancer on employment status, financial situation, and quality of life

Conditions: Breast Cancer

Summary: the purpose of this study is to learn more about how being treated for breast cancer affects patients' employment, financial situation, and quality of life on a short-term basis and on a long term basis. most studies of employment after breast cancer have focused on caucasian women.this study will evaluate the impact of breast cancer on the lives of women from different ethnic groups.


Eligibility criteria:
inclusion criteria: breast cancer survivors * pathologic diagnosis of stage i-iii breast cancer * paid employment (full time or part time) at time of consent or in the three months prior to diagnosis * age 18 to 64 years (inclusive) * the ability to give informed consent in chinese (mandarin), english, korean, or spanish.at msk, new york presbyterian queens and queens medical associates at nyc health \& hospitals/ lincoln medical center, patients must be able to give consent in english or spanish. * at the time of enrollment, participants must still be undergoing chemotherapy, undergoing radiation therapy, or planning surgery unless surgery is to be the only treatment modality. those for whom treatment consists of surgery alone may have had their operation no more than 2 months prior to study enrollment. participants need not have undergone surgical reconstruction prior to enrollment if the plan is to delay this procedure until after primary treatment is completed. comparison group paid employment (full time or part time) at the time of consent * age 18 to 64 years (inclusive) and within an age range that is 5 years above or below that of the nominating or matched survivor * the ability to give informed consent in the same language as the nominating survivor * membership in the same ethnic group as the nominating survivor * not treated for cancer in the past year (other than non-melanoma skin cancer) exclusion criteria: * n/a

Keywords: sociodemographic ethnicity work-related health system qol questionnaires 10-071
telerehabilitation for multiple sclerosis

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is a neurodegenerative disease affecting the central nervous system and is a leading cause of disability in young adults. it often produces strength deficits. exercise has been shown to improve strength, mobility, and quality of life while reducing fatigue. telerehabilitation offers a convenient, accessible alternative for ms patients. this study explores the use of an ai-powered application for prescribing and monitoring strength exercises, ensuring continuous feedback and adherence. methods: randomized clinical trial. intervention of 3 weekly strength training ses-sions for 20 weeks, patients in the experimental group used the ai application, while patients in the control group followed the conventional method, paper-based exercises with access to videos.


Eligibility criteria:
inclusion criteria: * diagnosis of multiple sclerosis according to the mcdonald criteria 2017: * age between 35 and 60 years. * score on the expanded disability status scale in multiple sclerosis by kurtzke (edss) between 2 and 6 points. * patients who do not require assistive devices for home mobility. * patients with no changes in disease-modifying treatment in the last 3 months. * patients who have understood, completed, and signed the informed consent and the study information sheet. exclusion criteria: * patients who have been regularly performing strength exercises for more than 3 months prior. * moderate/severe cognitive impairment that may interfere with the understanding and/or execution of the study. * history of alcohol and/or drug abuse. * presence of a relapse and/or treatment with corticosteroids within the four weeks prior to the start of the study. * patients with severe comorbidities other than ms that may pose a risk for following the exercise guidelines or for their participation in the study for other reasons.

Keywords: artificial intelligence exercise multiple sclerosis physical therapy strength telerehabilitation
meal timings, appetite, mood and weight loss in individuals on a commercial intermittent fasting programme

Conditions: Weight Loss

Summary: although individuals following commercial intermittent fasting programmes consume meal replacement products during fasting days, further behavioural variables such as time of food consumption, sleep quality and duration, appetite and mood may significantly impact weight loss and intervention success. this project aims to assess behavioural patterns (dietary intake, sleep, meal timing, physical activity), mood and appetite on both fasting and non-fasting days and to investigate whether these are associated with weight loss.


Eligibility criteria:
inclusion criteria: * those responding to adverts on the lighterlife fast challenge social media channels will be asked if they would like to participate exclusion criteria: * those without access to a smart phone or laptop will not be eligible to take part in the study due to the need to report variables daily
evaluation of the daly on a cohort of patients with indolent systemic mastocytosis

Conditions: Mastocytosis, Indolent Systemic

Summary: mastocytosis is a group of pathologies characterized by the accumulation and/or clonal proliferation of abnormal mast cells in various organs. the impact of mastocytosis on health, quality of life, the psychoaffective sphere and on professional life constitutes the burden of this disease. the daly is the disability-adjusted life expectancy, which takes into account the life expectancy and the number of years "lost" due to illness, disability or early death. due to the major impact of the disease this study evaluates the daly in indolent mastocytosis patients

mastocytosis is a group of pathologies characterized by the accumulation and/or clonal proliferation of abnormal mast cells in various organs. mastocytosis is a rare disease with an estimated prevalence of between 1/20,000 and 1/40,000. the impact of mastocytosis on health, quality of life, the psychoaffective sphere and on professional life constitutes the burden of this disease. this is probably important but very little studied so far. the daly is the disability-adjusted life expectancy. it is calculated by subtracting from life expectancy the number of years "lost" due to illness, disability or early death. ignorance of the disease and diagnostic error cause significant distress in patients. in our clinical experience, the impact of the disease on the personal, social, and professional life of our patients is major. it therefore seems important to better specify the impact on the quality of life and the costs of this pathology. the main objective of this study is to evaluate the daly in indolent mastocytosis patients from the ceremast reference center of the toulouse university hospital.

Eligibility criteria:
inclusion criteria: * having expressed their non opposition to participate in this study * diagnosed with indolent mastocytosis and cared for in the ceremast reference center in toulouse exclusion criteria: * patient with a form of mastocytosis other than msi * patient under legal protection, guardianship or curatorship

Keywords: daly mastocytosis quality of life
quality of life, anxiety and fatigue level of parkison's patients with color therapy

Conditions: Parkinson

Summary: the aim of this study was to investigate the effect of color therapy on quality of life, anxiety and fatigue levels in patients with parkinson's disease.

color therapy aims to balance and heal our body's energy centers using the seven color spectrum, which helps to promote our body's own healing process. thus good health and well-being is achieved through the balance of all these energies. color therapy basically consists of color and character analysis with name, color therapy with chakras, programming of the pendulum, chakras and color application, color application with water, color application with colored light device.

Eligibility criteria:
inclusion criteria: * having been diagnosed with parkinson's disease for at least 6 months, * those who have not taken sleeping pills or sedative drugs, * not having undergone brain stimulation surgery, * do not have a physical illness or cognitive disability that would prevent them from understanding the education provided, and do not have a diagnosis of a psychiatric disease, * according to the parkinson's fatigue scale, the scale score is \>8 * the patient or someone living in the same house with the patient is literate, * patients have no vision problems. exclusion criteria: * parkinson patients who did not agree to participate in the research

Keywords: color therapy
effects of iastm along with comprehensive corrective exercise program in upper cross syndrome.

Conditions: Upper Cross Syndrome

Summary: this study will see the effects of iastm along with comprehensive corrective exercise program in upper cross syndrome through their effects on pain and cervical ranges as well as postural improvement. our study targets both male and female population. in the reference study only male population was targeted which did not show effects of both techniques on the female population though females have high stress levels which may alter results.

the upper cross syndrome involves stiffness of levator scapulae, pectoralis major and upper trapezius muscles and serratus anterior, deep neck flexors, rhomboids, middle and lower trapezius and scalene muscles weakness. numerous bodily abnormalities such as headache, early deterioration of cervical spine and loss of cervical spine curve can be brought on by this syndrome. this syndrome can also result in thoracic spine abnormality and impaired glenohumeral joint biomechanics. upper cross syndrome develops abnormality in head, neck and shoulder and develops in upper 1⁄4 of the trunk. the underlying causative agents of upper cross syndrome are long surgeries, weakness, female gender, disability and poor posture. it was a randomized, controlled trial, conducted among patient with upper cross syndrome with sample size was 44 by using g- power software. group a will be given iastm with graston's tool and comprehensive corrective exercise program and group b will receive only comprehensive corrective exercise program. the protocol will consist of 12 sessions in total with 3 sessions a week 45 minutes / session for both groups. assessment will be at baseline then after 2 weeks after that 2 weeks home plan for exercises and then after 4 weeks assessment will be done. only pain will be assessed on alternative days

Eligibility criteria:
inclusion criteria: age 18-40 years. * diagnosed patients with the upper crossed syndrome who have chronic neck * pain for more than 3 months. * having neck pain scoring more than 3 on the numeric pain scale were included * in this study. * any abnormality in the position and rhythm of the scapula, as measured by the scapular dyskinesis test, having postural changes such as excessive thoracic kyphosis (≥42°), forward head (≥44°) or round shoulder (≥49°) as measured by flexicurve and photogrammetry. * both male and female population will be included exclusion criteria: the subjects with any previous surgery, any type of infection hypersensitive skin diabetes mellitus type ii having traumatic injury psychological disorder manual therapy contraindication like osteoporosis, infection, disc- herniation acute inflammation, burn scars, closed /non-complicated fractures and open wound.

Keywords: forward head angle pain rom rounded shoulder
long-term safety of latanoprostene bunod ophthalmic solution 0.024% in japanese subjects with oag or oht

Conditions: Glaucoma; Ocular Hypertension

Summary: the objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (qd) over a 1-year treatment period.


Eligibility criteria:
inclusion criteria: * subjects must have a diagnosis of open angle glaucoma (oag) (including normal-tension glaucoma \[ntg\],pigmentary or pseudoexfoliative glaucoma), or ocular hypertension (oht) in one or both eyes. * subjects must meet the following iop requirements at visit 3 (eligibility, day 0\[after washout for the subjects already on treatment\]): mean/median iop ≥15 mmhg and ≤36 mmhg at 10 am in at least 1 eye; and iop ≤36 mmhg in both eyes. * subjects with a corrected decimal visual acuity (va) or a best-corrected decimal visual acuity (bcva) of 0.5 or better in both eyes. exclusion criteria: * subjects who are unable to discontinue contact lens use during and for 15 minutes following instillation of study drug and during study visits. * subjects who are unable to discontinue other eye drop medications such as artificial tears for 15 minutes prior to and 15 minutes after instillation of study drug. * subjects with a central corneal thickness greater than 600 μm in either eye. * subjects with any condition that prevents reliable applanation tonometry in either eye. * subjects with advanced glaucoma with a mean deviation (md) \< -12 db, a history of split fixation, or a field loss threatening fixation in either eye. * subjects with any condition that prevents clear visualization of the fundus. * subjects who are monocular (fellow eye is absent). * subjects with aphakia in either eye. * subjects with an active corneal disease in either eye. * subjects with severe dry eye in either eye. * subjects with a history/diagnosis of a clinically significant or progressive retinal disease in either eye. * subjects with very narrow angles and subjects with angle closure congenital, or secondary glaucoma, and subjects with history of angle closure in either eye. * subjects with any intraocular infection or inflammation in either eye within 3 months prior to visit 1 (screening). * subjects with a history of ocular laser surgery in either eye within the 3 months (90 days) prior to visit 1 (screening). * subjects with a history of incisional ocular surgery or severe trauma in either eye within 3 months prior to visit 1 (screening).
push-it continuing enteral feeds for tracheostomy

Conditions: Tracheostomy Complication; Critical Illness; Nutritional Deficiency

Summary: the goal of this clinical trial is to evaluate nutrition administration in the time around the tracheostomy in patients with breathing tubes. the main questions it aims to answer are: * will continuing nutrition up to the time of surgery (tracheostomy) decrease nutrition interruptions, thereby increasing food intake? * does continuing nutrition up to the time of surgery increase instances of food going into the lungs or lung infections? researchers will compare patients who have nutrition withheld 6 hours prior to surgery versus those who receive nutrition up until the time of surgery to see if there are differences in food intake, instances of food entering the lungs or lung infections.

malnutrition is a significant problem in the critically ill, however with busy operating room schedules, we often find that feeds are interrupted repetitively prior to elective surgery. these interruptions are practiced based on the american society of anesthesiologist guidelines for fasting intervals for elective surgery. these guidelines, however, were not created for critically ill, intubated patients. the theoretical concern for an increased risk of aspiration with continuation of enteral feeds up to the time of surgery persists without supporting evidence. thus, there is a need for a universal evidence-based guideline on perioperative enteral feeding to benefit critical care patients. to this end, the goal of the present study is to implement a protocol designed to decrease the interruption of enteral feeds in critical care patients undergoing tracheostomy and prospectively evaluate whether this leads to a quantitative increase in nutritional intake without increasing the risk of aspiration. additionally, we hope that increasing quantitative nutrition may decrease morbidity especially in the small subset of patients where feed interruptions occur repetitively. if the aims of the project are achieved, the data obtained from this study will be used to create an evidence-based platform from which physicians can practice. this will end the anecdotal controversy regarding perioperative tube feed management for tracheostomy; thereby increasing quantitative nutrition and hopefully improving the care of critically ill patients.

Eligibility criteria:
inclusion criteria: * 18 years or older * admitted to the intensive care unit (icu) * intubated and require tracheostomy exclusion criteria: * under 18 years * unable to obtain informed consent * deemed clinically brain dead within 7 days of enrollment * transitioned to comfort measures within 7 days of enrollment * pregnant patients * prisoners

Keywords: tube feed nil per os aspiration pneumonia nutritional delivery
home-based tdcs and mindfulness-based meditation for self-management of clinical pain and symptoms

Conditions: Osteo Arthritis Knee

Summary: the purpose of this study is to determine the effects of active transcranial direct current stimulation (tdcs) paired with active mindfulness-based meditation (mbm) on clinical pain,osteo arthritis (oa)-related clinical symptoms, physiopsychological pain processing and participant satisfaction with treatment in patients with knee oa.


Eligibility criteria:
inclusion criteria: * have symptomatic knee oa based on american college of rheumatology clinical criteria * have had knee oa pain in the past 3 months with an average of at least 30 on a 0-100 nrs for pain, * can speak and read english * have no plan to change medication regimens for pain throughout the trial exclusion criteria: * history of brain surgery, brain tumor, seizure, stroke, or intracranial metal implantation * systemic rheumatic disorders, including rheumatoid arthritis,systemic lupus erythematosus, and fibromyalgia * alcohol/substance abuse * diminished cognitive function that would interfere with understanding study procedures (i.e., mini-mental status exam score ≤ 23) * pregnancy or lactation * prosthetic knee replacement or non-arthroscopic surgery to the affected knee * hospitalization within the preceding year for psychiatric illness * no access to a device that can be used for secure videoconferencing for real-time remote supervision.

Keywords: meditation
atkins diet and prostate cancer clinical trial

Conditions: Prostate Cancer

Summary: this study will test the hypothesis that a low-carbohydrate atkins diet will prevent or at least minimize the metabolic consequences of androgen deprivation therapy (adt).

androgen deprivation therapy (adt) is the standard treatment for advanced prostate cancer. while a very effective anti-cancer treatment, adt is associated with significant toxicity including but not limited to major metabolic disturbances including impaired glucose tolerance, insulin resistance, and weight gain. we hypothesize that limiting carbohydrates within the diet will prevent or at least minimize these consequences.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed adenocarcinoma of the prostate 2. scheduled to initiate adt with an anticipated duration of ≥ 6 months 3. overweight or obese (body mass index ≥ 25 kg/m2) exclusion criteria: 1. symptomatic metastatic disease 2. myocardial infarction within 6 months 3. treatment with medications known to affect insulin or glucose levels (i.e. insulin, oral hypoglycemics, prednisone, etc.) 4. patient consuming a low-carbohydrate diet 5. medical conditions or co-morbidities that preclude participation in the protocol 6. vegetarians

Keywords: prostate cancer atkins